Former US President Donald Trump has announced plans to impose tariffs of up to 100% on certain imported pharmaceutical products. The move aims to reduce drug prices in the United States and encourage companies to shift manufacturing back to America.
Key Details of the Proposal
The tariff will primarily target branded and patented medicines manufactured outside the US. Companies that do not reduce drug prices or invest in American manufacturing facilities could face the full 100% duty.
According to the plan, pharmaceutical firms will have around 120 days to negotiate price-reduction agreements with the US government. Those committing to build manufacturing plants in the US may initially face a lower tariff of about 20%, which could increase later if commitments are not met.
Generic medicines are expected to remain exempt from the tariff, as they make up the majority of prescriptions in the United States.
Potential Impact
The proposal has raised concerns among global pharmaceutical companies. Industry experts warn that such high tariffs could disrupt international supply chains and increase costs for drugmakers exporting to the US market.
However, the policy may also encourage international firms to invest more in American manufacturing facilities to avoid the tariffs.
Effect on India
India is a major exporter of generic drugs to the United States. Since generics are likely to be exempted, the immediate impact on Indian pharmaceutical exports is expected to be limited. Still, any long-term shift in US policy could affect the broader industry.